Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients

Pediatric Drugs

Volumn 16, Issue 4, 2014, Pages 337-341

  Kamal El Din, Mennat Allah ^a   Farhan, Marwa Salah ^a   El Shiha, Randa Ibrahim ^b   El Kaffas, Rania Mohammed Helmy ^a   Mousa, Somaia Mohammed ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b MINISTRY OF HEALTH   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CYP2C9 GENE; DNA POLYMORPHISM; EGYPT; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; HUMAN; MAINTENANCE DRUG DOSE; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VKORC1 GENE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; PRESCHOOL CHILD;

ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2C9; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84905500119     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0073-5     Document Type: Article

References (19)

1. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625-9.
2. Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics. 2012;13(4):429-40.
3. Mazzaccara C, Conti V, Liguori R, et al. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS ONE. 2013;8(8):e71505.
4. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics. 2010;11(4):493-6.
5. Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol. 2011;72(3):451-3.
6. Hamdy SI, Hiratsuka M, Narahara K, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53(6):596-603. (Pubitemid 34621785)
7. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011;21(3):130-5.
8. El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol. 2012;34(5):517-24.
9. Nowak-Göttl U, Dietrich K, Schaffranek D, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116(26):6101-5.
10. Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002;54(5):518-21. (Pubitemid 35356878)
11. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23(10):1110-6.
12. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68(5):541-55.
13. Ruud E, Holmstrøm H, Bergan S, Wesenberg F. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer. 2008;50(3):710-3. (Pubitemid 351155871)
14. Biss TT, Avery PJ, Brandão LR, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119(3):868-73.
15. Shaw K, Amstutz U, Hildebrand C, et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014. doi:10.1002/pbc.24932.
16. Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119(3):861-7.
17. Kato Y, Ichida F, Saito K, et al. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet. 2011;26(3):295-9.
18. Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol. 2013;34(4):984-90.
19. Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 2008;9(9):1331-46.